Altamira Therapeutics Ltd. (CYTOF)
| Market Cap | 405.00K +38.1% |
| Revenue (ttm) | n/a |
| Net Income | -5.65M |
| EPS | -1.31 |
| Shares Out | 5.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,969 |
| Open | 0.0771 |
| Previous Close | 0.0740 |
| Day's Range | 0.0771 - 0.0771 |
| 52-Week Range | 0.0497 - 0.1479 |
| Beta | 2.79 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 4, 2026 |
About Altamira Therapeutics
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. The company develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through xPhore platform; and offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens It is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; and AM-125 that is in post phase II cli... [Read more]
Financial Performance
Financial StatementsNews
Altamira Therapeutics Announces Publication Highlighting Potential of RNA Nanoparticles for Disease-Modifying Treatment of Osteoarthritis
HAMILTON, BM / ACCESS Newswire / April 13, 2026 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCID:CYTOF), a company dedicated to developing and commercializing RNA delivery technology ...
Altamira Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
Expanding nucleic acid delivery business with new applications Ongoing optimization of cost structure Advancing plans for spin-off of nucleic acid delivery business and continuing strategic reposition...
Altamira Therapeutics Earnings release: H2 2025
Altamira Therapeutics released its H2 2025 earnings on March 31, 2026, summarizing the period's financial results.
Altamira Therapeutics Announces Release Date for 2025 Annual Report and Financial Statements
HAMILTON, BM / ACCESS Newswire / March 24, 2026 / Altamira Therapeutics ("Altamira" or the "Company") (OTCID:CYTOF) today announced that it will release its annual report and financial statements for ...
Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Bentrio Nasal Spray
HAMILTON, BM / ACCESS Newswire / February 13, 2026 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCID:CYTOF), a company dedicated to developing and supplying nucleic acid delivery techn...
Altamira Therapeutics to Present at mRNA-Based Therapeutics Summit
HAMILTON, BERMUDA / ACCESS Newswire / January 23, 2026 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCID:CYTOF), a company dedicated to developing and commercializing nucleic acid deli...
Altamira Therapeutics Announces Market Approval of Bentrio Nasal Spray in China
Regulatory clearance of Bentrio in allergic rhinitis for Mainland China Nearly 200 million Chinese estimated to suffer from allergic rhinitis Bentrio to be launched by partner Nuance Pharma HAMILTON, ...
Altamira Therapeutics Slides: Corporate presentation
Altamira Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 26, 2025.
Altamira Therapeutics Announces Certification of Bentrio Nasal Spray under Medical Device Regulation
Conformity with stringent new EU regulations for medical devices confirmed Allows for commercialization of Bentrio in EU member states; facilitates regulatory approval in various other countries Major...
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of DNA Molecules
Demonstrated feasibility of effective DNA delivery with Company's xPhore™ nanoparticle technology DNA delivery technology to be offered as GenePhore™ to biotech / pharma companies Addressing large and...
Altamira Therapeutics Earnings Call Transcript: H1 2025
Operating loss and net loss declined significantly year-over-year due to cost optimization and finance income. The RNA delivery business advanced with new partnerships and a planned spin-off, while legacy assets progressed in manufacturing and regulatory milestones.
Altamira Therapeutics Earnings release: H1 2025
Altamira Therapeutics released its H1 2025 earnings on August 29, 2025, summarizing the period's financial results.
Altamira Therapeutics Provides Business Update and First Half 2025 Financial Results
Company to host webcast today at 8.00 a.m. ET Growing portfolio of RNA delivery clients and programs Advancing plans for partial spin-off of RNA delivery activities Continued adjustment of cost struct...
Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025
HAMILTON, BERMUDA / ACCESS Newswire / August 26, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery techn...
Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Intranasal Betahistine
HAMILTON, BM / ACCESS Newswire / July 15, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing therapeutics that address important unmet med...
Altamira Therapeutics Announces Collaboration on Circular RNA Delivery
Hamilton, May 27, 2025 (GLOBE NEWSWIRE) -- Exploring use of Altamira's RNA nanoparticles in conjunction with circular RNA payloads Project collaboration partner will have option to negotiate licensing...
Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results
Hamilton, Bermuda, April 30, 2025 (GLOBE NEWSWIRE) -- Management to host conference call today, April 30, at 8:00 a.m. EDT RNA delivery business progressing with platform development, new applications...
Altamira Therapeutics Earnings Call Transcript: H2 2024
Progress in RNA delivery and legacy asset monetization was offset by a Nasdaq delisting, prompting a strategic shift to private equity funding and a planned spinoff of the RNA business. Financials showed higher operating loss but improved cash position, with significant reduction in expenses expected post-spinoff.
Altamira Therapeutics Annual report: H2 2024
Altamira Therapeutics has published its H2 2024 annual report on April 30, 2025.
Altamira Therapeutics Earnings release: H2 2024
Altamira Therapeutics released its H2 2024 earnings on April 30, 2025, summarizing the period's financial results.
Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call on April 30, 2025
Hamilton, Bermuda, April 25, 2025 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB: CYTOF), a company dedicated to developing and commercializing RNA delivery techno...
Altamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray Patent
Hamilton, March 07, 2025 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (OTCQB:CYTOF) today announced that the U.S. Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for a patent ...
Altamira Therapeutics Slides: Company Presentation
Altamira Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on January 6, 2025.
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technolo...
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB: CYTOF), a company dedicated to developing and commercializing RNA delivery technol...